Secondary myelodysplastic syndrome after small cell lung cancer and esophageal cancer
Version of Record online: 7 JUN 2005
Journal of Gastroenterology and Hepatology
Volume 20, Issue 9, pages 1318–1321, September 2005
How to Cite
OTSUKA, Y., KONISHI, T., NARA, S., FURUSHIMA, K., NAKAJIMA, K. and SHIMADA, H. (2005), Secondary myelodysplastic syndrome after small cell lung cancer and esophageal cancer. Journal of Gastroenterology and Hepatology, 20: 1318–1321. doi: 10.1111/j.1440-1746.2005.03838.x
- Issue online: 10 AUG 2005
- Version of Record online: 7 JUN 2005
- Accepted for publication 16 September 2004.
- chemoradiation therapy;
- esophageal cancer;
- myelodysplastic syndrome;
- small cell lung cancer
Abstract A 50-year-old man was referred to our department with esophageal cancer. He had past history of small cell lung cancer treated with chemoradiation therapy 10 years prior. The disease was evaluated as complete remission after chemoradiation therapy and no recurrence had been observed. Esophagectomy accompanying postoperative chemotherapy was applied, but he died of secondary myelodysplastic syndrome with its acute myeloblastic transformation. Risk evaluation revealed a high incidence of esophageal cancer after radiation therapy and hematological malignancies after chemoradiation therapy in usual regimen with topoisomerase inhibitor or alkylating agents. Chemoradiation therapy is thought to be one of a few highly effective therapeutic alternatives and many complete remission cases have been reported in small cell lung cancer or esophageal cancer. In post-therapeutic follow up of patients with such past therapeutic histories, we should be cautious about secondary malignancies even if primary malignant disease was evaluated as complete remission in long past history.